Presentation of the portfolio of workflow solutions, next-generation CT technology; aimed at treating today’s pain points in radiology
Announced Collaboration Agreements to Expand Offerings on New Calantic Medical Imaging PlatformMT Digital solutions in key disease areas
Presentation of new scientific data on the experimental contrast agent
PITTSBURGH, November 23, 2022–(BUSINESS WIRE)–As international imaging leaders gather for the 2022 Radiological Society of North America (RSNA) Annual Meeting, Bayer Radiology, a leader in diagnostic imaging, will present its portfolio of products and solutions aimed at solving today’s most pressing problems facing the field of radiology. In addition, Bayer will present new scientific data on an investigational contrast agent. RSNA 2022 will take place from November 27 to December 1 in Chicago.
Bayer’s focus areas at RSNA represent the company’s commitment to help address staffing shortages with solutions focused on patient throughput and workflow efficiency to drive automation and standardization , investing in science for the benefit of patients and their doctors, and harnessing the vast potential of data and AI.
Next-generation CT technology and workflow solutions highlight integrated offerings that manage complexity and deliver accurate diagnostic information more efficiently.
Bayer’s introduction of Injector Management* software enables consistency and standardization by providing the ability to share common protocols across connected injectors. *not yet commercially available.
Bayer will showcase its next-generation CT technology, MEDRAD Centargo CT Injection System (Centargo) at RSNA (Centargo is 510(k) pending and not available for sale in the U.S. The latest addition to Bayer’s CT portfolio is designed to improve workflow efficiency with design features that work in conjunction with Bayer’s product portfolio to bring innovative technology to the imaging suite and introduce new technologies to the areas of patient setup .
EExpanding AI offerings on CalanticMT Digital Solutions
Bayer also announces collaboration agreements with application developers Quantib, ClariPi and EXINI Diagnostics to strategically expand the offering on its Calantic medical imaging platformMT Digital solutions. The platform, which was launched recently, provides access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer expands the options already available for chest and neurological diseases on the platform by including tools that aim to facilitate breast and prostate imaging.
Introducing the Calantic App Accelerator ProgramMT SPARK
Additionally, Bayer recently launched CalanticMT SPARK, a new accelerator program for medical imaging application developers to further drive innovation in AI in radiology. The program will initially focus on North America and Europe and is expected to expand to other regions, including Asia-Pacific. Bayer offers a targeted program to accelerate market readiness for early-stage projects and deals, providing advice spanning medical, regulatory, reimbursement expertise and market access. Leveraging the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK offers program participants a potential route to commercialization and distribution through Calantic Digital Solutions. Details of Calantic SPARK will be on display at Bayer’s booth as well as the AI Showcase Theater at RSNA.
The role of a high relaxivity contrast agent in CNS and MRA imaging
Monday, November 28, 9:30 a.m. (CT)
From AI design to validation; The role of AI orchestration platforms
Presentation of the Al Showcase Theater
Monday, November 28, 1:00 p.m. (CT)
Sparks of collaboration, How Bayer engages with the startup ecosystem.
Monday, November 28, 11:00 a.m. (CT)
Venue: AI Theater
Liver Imaging Techniques and Considerations.
Tuesday, November 29, 10:30 a.m. (CT)
Virtual Product Theater
Drive AI innovation to assess reimbursable applications
Wednesday, November 30, 3:00 p.m. (CT)
Scientific presentation on a new experimental molecular entity
Bayer will present the results of the first clinical trial data on an investigational contrast agent. Gadoquatrane is a gadolinium-based contrast agent in Phase II development. The study examined the pharmacokinetics, including excretion routes, safety, and tolerability of gadoquatrane in healthy volunteers.
Bayer is a global company with core competencies in the areas of life sciences healthcare and nutrition. Its products and services are designed to help people and the planet prosper by supporting efforts to master the major challenges posed by a growing and aging global population. Bayer is committed to fostering sustainable development and generating a positive impact on its activities. At the same time, the Group aims to increase its profitability and create value through innovation and growth. The Bayer brand is synonymous with trust, reliability and quality around the world. In fiscal year 2021, the Group employed approximately 100,000 people and generated revenue of €44.1 billion. R&D expenditure before exceptional items amounted to 5.3 billion euros. For more information, visit www.bayer.com.
More information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on twitter: @BayerPharma
This press release may contain forward-looking statements based on current assumptions and forecasts made by Bayer’s management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on Bayer’s website at www.bayer.com. The company assumes no responsibility for updating these forward-looking statements or conforming them to future events or developments.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221122005765/en/
Jennifer May, phone, 412-656-8192